Hydroxychloroquine sulfate is widely prescribed in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis, and related autoimmune diseases, and it has largely superseded the use of chloroquine phosphate for these conditions. Furthermore, hydroxychloroquine is now being evaluated for other medical uses, including control of blood glucose levels and as an adjunct to chemotherapy for cancer. Although hydroxychloroquine has relatively few systemic adverse effects, a specter of potential retinal toxicity hangs over its use, and regular screening is necessary to detect early changes in the retina before vision is compromised.1 The study by Nika et al2 in JAMA Ophthalmology shows that despite the risk of toxicity, many patients using hydroxychloroquine for SLE and related disorders are still not seeing eye care professionals or getting appropriate diagnostic tests. This is a wake-up call to physicians who prescribe this drug.
Marmor MF, Melles RB. Hydroxychloroquine and the Retina. JAMA. 2015;313(8):847–848. doi:10.1001/jama.2014.14558
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: